GenMark Diagnostics, Inc. (NASDAQ:GNMK) insider Hany Massarany sold 1,588 shares of GenMark Diagnostics stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $7.24, for a total transaction of $11,497.12. Following the completion of the sale, the insider now owns 371,209 shares of the company’s stock, valued at approximately $2,687,553.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Hany Massarany also recently made the following trade(s):

  • On Monday, August 21st, Hany Massarany sold 8,311 shares of GenMark Diagnostics stock. The shares were sold at an average price of $9.45, for a total transaction of $78,538.95.

Shares of GenMark Diagnostics, Inc. (NASDAQ GNMK) traded down $3.04 during mid-day trading on Friday, reaching $4.26. 7,007,583 shares of the company’s stock were exchanged, compared to its average volume of 359,599. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.39 and a current ratio of 3.60.

GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.02). The business had revenue of $11.60 million for the quarter, compared to the consensus estimate of $14.56 million. GenMark Diagnostics had a negative net margin of 116.76% and a negative return on equity of 113.51%. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.27) EPS. equities research analysts forecast that GenMark Diagnostics, Inc. will post -1.06 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “GenMark Diagnostics, Inc. (GNMK) Insider Sells $11,497.12 in Stock” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/03/genmark-diagnostics-inc-gnmk-insider-sells-11497-12-in-stock.html.

Several research firms have recently weighed in on GNMK. Bank of America Corporation began coverage on shares of GenMark Diagnostics in a research note on Monday, September 18th. They issued a “buy” rating and a $13.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of GenMark Diagnostics in a research note on Wednesday, October 4th. BTIG Research reiterated a “buy” rating and issued a $13.00 price objective on shares of GenMark Diagnostics in a research note on Thursday, August 31st. Canaccord Genuity reiterated a “buy” rating and issued a $14.00 price objective on shares of GenMark Diagnostics in a research note on Monday. Finally, Raymond James Financial, Inc. reiterated a “market perform” rating on shares of GenMark Diagnostics in a research note on Friday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $12.20.

A number of hedge funds have recently made changes to their positions in the business. FMR LLC increased its stake in GenMark Diagnostics by 13.6% during the 2nd quarter. FMR LLC now owns 8,020,502 shares of the medical equipment provider’s stock valued at $94,883,000 after purchasing an additional 962,822 shares in the last quarter. JPMorgan Chase & Co. increased its stake in GenMark Diagnostics by 15.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,097,767 shares of the medical equipment provider’s stock valued at $48,476,000 after purchasing an additional 559,629 shares in the last quarter. Jennison Associates LLC increased its stake in GenMark Diagnostics by 0.7% during the 3rd quarter. Jennison Associates LLC now owns 3,567,001 shares of the medical equipment provider’s stock valued at $34,350,000 after purchasing an additional 25,254 shares in the last quarter. HighTower Advisors LLC increased its stake in GenMark Diagnostics by 12.7% during the 2nd quarter. HighTower Advisors LLC now owns 2,360,984 shares of the medical equipment provider’s stock valued at $27,930,000 after purchasing an additional 266,969 shares in the last quarter. Finally, Artisan Partners Limited Partnership increased its stake in GenMark Diagnostics by 25.2% during the 2nd quarter. Artisan Partners Limited Partnership now owns 2,252,831 shares of the medical equipment provider’s stock valued at $26,651,000 after purchasing an additional 453,329 shares in the last quarter.

About GenMark Diagnostics

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.